Table of Contents Author Guidelines Submit a Manuscript
Mediators of Inflammation
Volume 2012, Article ID 789859, 9 pages
http://dx.doi.org/10.1155/2012/789859
Research Article

Effects of Telbivudine Treatment on the Circulating CD4+ T-Cell Subpopulations in Chronic Hepatitis B Patients

1Institute of Immunology, Third Military Medical University, PLA, Chongqing 400038, China
2Department of Pathology and Experimental Medicine, 306 Hospital, PLA, Beijing 100101, China
3Department of Health Care, Southwest Hospital, Third Military Medical University, Chongqing 400038, China
4Department of Dermatology, 105th Hospital, PLA, Hefei 230001, China
5Department of Infectious Diseases, Southwest Hospital, Third Military Medical University, Chongqing 400038, China
6Ministry of Education Key Laboratory of Child Development and Disorders, Pediatric Research Institute, Children's Hospital of Chongqing Medical University, Chongqing 400014, China

Received 26 November 2011; Accepted 12 February 2012

Academic Editor: Teresa Zelante

Copyright © 2012 Yanhua Zheng et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. Y. F. Liaw and C. M. Chu, “Hepatitis B virus infection,” The Lancet, vol. 373, no. 9663, pp. 582–592, 2009. View at Publisher · View at Google Scholar · View at Scopus
  2. L. G. Guidotti and F. V. Chisari, “Immunobiology and pathogenesis of viral hepatitis,” Annual Review of Pathology, vol. 1, pp. 23–61, 2006. View at Publisher · View at Google Scholar · View at Scopus
  3. M. K. Maini, C. Boni, G. S. Ogg et al., “Direct ex vivo analysis of hepatitis B virus-specific CD8+ T cells associated with the control of infection,” Gastroenterology, vol. 117, no. 6, pp. 1386–1396, 1999. View at Google Scholar · View at Scopus
  4. A. Bertoletti and N. V. Naoumov, “Translation of immunological knowledge into better treatments of chronic hepatitis B,” Journal of Hepatology, vol. 39, no. 1, pp. 115–124, 2003. View at Publisher · View at Google Scholar · View at Scopus
  5. B. Rehermann, P. Fowler, J. Sidney et al., “The cytotoxic T lymphocyte response to multiple hepatitis B virus polymerase epitopes during and after acute viral hepatitis,” Journal of Experimental Medicine, vol. 181, no. 3, pp. 1047–1058, 1995. View at Publisher · View at Google Scholar · View at Scopus
  6. O. Franzese, P. T. F. Kennedy, A. J. Gehring et al., “Modulation of the CD8+-T-cell response by CD4+ CD25+ regulatory T cells in patients with hepatitis B virus infection,” Journal of Virology, vol. 79, no. 6, pp. 3322–3328, 2005. View at Publisher · View at Google Scholar · View at Scopus
  7. J. N. Stoop, R. G. Van Der Molen, C. C. Baan et al., “Regulatory T cells contribute to the impaired immune response in patients with chronic hepatitis B virus infection,” Hepatology, vol. 41, no. 4, pp. 771–778, 2005. View at Publisher · View at Google Scholar · View at Scopus
  8. G. B. Gaeta and G. Stornaiuolo, “Therapy of chronic hepatitis B: focus on telbivudine,” Digestive and Liver Disease, vol. 39, no. 3, pp. S372–S378, 2007. View at Publisher · View at Google Scholar · View at Scopus
  9. J. Dienstag, C. Easley, and P. Kirkpatrick, “Telbivudine,” Nature Reviews Drug Discovery, vol. 6, no. 4, pp. 267–268, 2007. View at Publisher · View at Google Scholar · View at Scopus
  10. J. L. Dienstag, R. D. Goldin, E. J. Heathcote et al., “Histological outcome during long-term lamivudine therapy,” Gastroenterology, vol. 124, no. 1, pp. 105–117, 2003. View at Publisher · View at Google Scholar · View at Scopus
  11. Y. F. Liaw, E. Gane, N. Leung et al., “2-Year GLOBE trial results: telbivudine Is superior to lamivudine in patients with chronic hepatitis B,” Gastroenterology, vol. 136, no. 2, pp. 486–495, 2009. View at Publisher · View at Google Scholar · View at Scopus
  12. R. Perrillo, “Benefits and risks of interferon therapy for hepatitis B,” Hepatology, vol. 49, no. 5, pp. S103–S111, 2009. View at Publisher · View at Google Scholar · View at Scopus
  13. C. Boni, A. Bertoletti, A. Penna et al., “Lamivudine treatment can restore T cell responsiveness in chronic hepatitis B,” Journal of Clinical Investigation, vol. 102, no. 5, pp. 968–975, 1998. View at Google Scholar · View at Scopus
  14. C. Boni, A. Penna, A. Bertoletti et al., “Transient restoration of anti-viral T cell responses induced by lamivudine therapy in chronic hepatitis B,” Journal of Hepatology, vol. 39, no. 4, pp. 595–605, 2003. View at Publisher · View at Google Scholar · View at Scopus
  15. C. Boni, A. Penna, G. S. Ogg et al., “Lamivudine treatment can overcome cytotoxic T-cell hyporesponsiveness in chronic hepatitis B: new perspectives for immune therapy,” Hepatology, vol. 33, no. 4, pp. 963–971, 2001. View at Publisher · View at Google Scholar · View at Scopus
  16. M. K. Maini, S. Reignat, C. Boni et al., “T cell receptor usage of virus-specific CD8 cells and recognition of viral mutations during acute and persistent hepatitis B virus infection,” European Journal of Immunology, vol. 30, no. 11, pp. 3067–3078, 2000. View at Publisher · View at Google Scholar · View at Scopus
  17. S. L. Tsai, I. S. Sheen, R. N. Chien et al., “Activation of Th1 immunity is a common immune mechanism for the successful treatment of hepatitis B and C: tetramer assay and therapeutic implications,” Journal of Biomedical Science, vol. 10, no. 1, pp. 120–135, 2003. View at Publisher · View at Google Scholar · View at Scopus
  18. Y. Chen, X. Li, B. Ye et al., “Effect of telbivudine therapy on the cellular immune response in chronic hepatitis B,” Antiviral Research, vol. 91, no. 1, pp. 23–31, 2011. View at Publisher · View at Google Scholar
  19. P. L. Yang, A. Althage, J. Chung et al., “Immune effectors required for hepatitis B virus clearance,” Proceedings of the National Academy of Sciences of the United States of America, vol. 107, no. 2, pp. 798–802, 2010. View at Publisher · View at Google Scholar · View at Scopus
  20. E. M. Janssen, E. E. Lemmens, T. Wolfe, U. Christen, M. G. Von Herrath, and S. P. Schoenberger, “CD4+ T cells are required for secondary expansion and memory in CD8+ T lymphocytes,” Nature, vol. 421, no. 6925, pp. 852–856, 2003. View at Publisher · View at Google Scholar · View at Scopus
  21. D. J. Shedlock and H. Shen, “Requirement for CD4 T cell help in generating functional CD8 T cell memory,” Science, vol. 300, no. 5617, pp. 337–339, 2003. View at Publisher · View at Google Scholar · View at Scopus
  22. C. L. Lai, E. Gane, Y. F. Liaw et al., “Telbivudine versus lamivudine in patients with chronic hepatitis B,” The New England Journal of Medicine, vol. 357, no. 25, pp. 2576–2588, 2007. View at Publisher · View at Google Scholar · View at Scopus
  23. J. Hou, Y. K. Yin, D. Xu et al., “Telbivudine versus lamivudine in Chinese patients with chronic hepatitis B: results at 1 year of a randomized, double-blind trial,” Hepatology, vol. 47, no. 2, pp. 447–454, 2008. View at Publisher · View at Google Scholar · View at Scopus
  24. Y. Jiang, Z. Ma, G. Xin et al., “Th1 and Th2 immune response in chronic hepatitis B patients during a long-term treatment with adefovir dipivoxil,” Mediators of Inflammation, vol. 2010, Article ID 143026, 10 pages, 2010. View at Publisher · View at Google Scholar
  25. T. D. Shi, J. M. Zhang, X. F. Wang et al., “Effects of antiviral therapy with Telbivudine on peripheral iNKT cells in HBeAg(+) chronic hepatitis B patients,” Clinical and Experimental Medicine. In press. View at Publisher · View at Google Scholar
  26. Ö. Atan, G. Aksu, F. Özgenç et al., “Determination of intracellular Th1/Th2 type cytokines in lymphocytes of chronic hepatitis B patients treated with interferon-alpha,” Turkish Journal of Gastroenterology, vol. 21, no. 4, pp. 401–410, 2010. View at Publisher · View at Google Scholar
  27. L. S. Taams, M. Vukmanovic-Stejic, J. Smith et al., “Antigen-specific T cell suppression by human CD4+CD25+ regulatory T cells,” European Journal of Immunology, vol. 32, no. 6, pp. 1621–1630, 2002. View at Publisher · View at Google Scholar · View at Scopus
  28. J. N. Stoop, R. G. van der Molen, E. J. Kuipers, J. G. Kusters, and H. L. A. Janssen, “Inhibition of viral replication reduces regulatory T cells and enhances the antiviral immune response in chronic hepatitis B,” Virology, vol. 361, no. 1, pp. 141–148, 2007. View at Publisher · View at Google Scholar · View at Scopus
  29. X.-P. Nan, Y. Zhang, H.-T. Yu et al., “Inhibition of viral replication downregulates CD4+ CD25high regulatory T cells and programmed death-ligand 1 in chronic hepatitis B,” Viral Immunology, vol. 25, no. 1, pp. 21–28, 2012. View at Publisher · View at Google Scholar
  30. N. Alatrakchi and M. Koziel, “Regulatory T cells and viral liver disease,” Journal of Viral Hepatitis, vol. 16, no. 4, pp. 223–229, 2009. View at Publisher · View at Google Scholar · View at Scopus
  31. F. Cottrez and H. Groux, “Specialization in tolerance: innate CD4+CD25+ versus acquired Tr1 and Th3 regulatory T cells,” Transplantation, vol. 77, no. 1, pp. S12–S15, 2004. View at Google Scholar · View at Scopus
  32. Y. Ye, X. Xie, J. Yu et al., “Involvement of Th17 and Th1 effector responses in patients with hepatitis B,” Journal of Clinical Immunology, vol. 30, no. 4, pp. 546–555, 2010. View at Publisher · View at Google Scholar · View at Scopus
  33. Q. Wang, Y. Zheng, Z. Huang et al., “Activated IL-23/IL-17 pathway closely correlates with increased Foxp3 expression in livers of chronic hepatitis B patients,” BMC Immunology, vol. 12, 2011. View at Publisher · View at Google Scholar
  34. J. Y. Zhang, Z. Zhang, F. Lin et al., “Interleukin-17-producing CD4+ T cells increase with severity of liver damage in patients with chronic hepatitis B,” Hepatology, vol. 51, no. 1, pp. 81–91, 2010. View at Publisher · View at Google Scholar · View at Scopus